Literature DB >> 35900690

Amelioration of intracerebroventricular streptozotocin-induced cognitive dysfunction by Ocimum sanctum L. through the modulation of inflammation and GLP-1 levels.

Bansy Patel1, Devang Sheth2, Amit Vyas1, Sunny Shah1, Sachin Parmar3, Chirag Patel4, Sandip Patel4, Jayesh Beladiya4, Sonal Pande4, Ketan Modi5.   

Abstract

DPP-4 inhibitors have been shown to reverse amyloid deposition in Alzheimer's disease (AD) patients with cognitive impairment. Ocimum sanctum L. leaves reported the presence of important phytoconstituents which are reported to have DPP-4 inhibitory activity. To investigate the effects of petroleum ether extract of Ocimum sanctum L. (PEOS) in Intracerebroventricular streptozotocin (ICV-STZ) induced AD rats. ICV-STZ (3 mg/kg) was injected bilaterally into male Wistar rats, while sham animals received the artificial CSF. The ICV-STZ-induced rats were administered with three doses of PEOS (100, 200, and 400 mg/kg, p.o.) for thirty days. All experimental rats were subjected to behaviour parameters (radial arm maze task and novel object recognition test), neurochemical parameters such as GLP-1, Aβ42, and TNF-α levels, and histopathological examination (Congo red staining) of the left brain hemisphere. PEOS significantly reversed the spatial learning and memory deficit exhibited by ICV-STZ-induced rats. Furthermore, PEOS also shows promising results in retreating Aβ deposition, TNF α, and increasing GLP-1 levels. The histopathological study also showed a significant dose-dependent reduction in amyloid plaque formation and dense granule in PEOS -treated rats as compared to the ICV-STZ induced rats (Negative control). The results show that extract of Ocimum sanctum L. attenuated ICV-STZ-induced learning and memory deficits in rats and has the potential to be employed in the therapy of AD.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Alzheimer’s disease; DPP-4 inhibitors; ICV-STZ; Intracerebroventricular streptozotocin; Ocimum sanctum; Radial arm maze test; Stereotaxic device

Mesh:

Substances:

Year:  2022        PMID: 35900690     DOI: 10.1007/s11011-022-01056-8

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.655


  20 in total

1.  Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice.

Authors:  Yanxing Chen; Zhihou Liang; Zhu Tian; Julie Blanchard; Chun-Ling Dai; Sonia Chalbot; Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  Mol Neurobiol       Date:  2013-08-31       Impact factor: 5.590

Review 2.  Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease?

Authors:  Sónia C Correia; Renato X Santos; George Perry; Xiongwei Zhu; Paula I Moreira; Mark A Smith
Journal:  Ageing Res Rev       Date:  2011-01-22       Impact factor: 10.895

Review 3.  DPP-4 inhibitors: a promising therapeutic approach against Alzheimer's disease.

Authors:  Efthalia Angelopoulou; Christina Piperi
Journal:  Ann Transl Med       Date:  2018-06

4.  An Animal Model to Test Reversal of Cognitive Decline Associated with Beta-Amyloid Pathologies.

Authors:  Farah Deba; Steven Peterson; Ayman K Hamouda
Journal:  Methods Mol Biol       Date:  2019

5.  Neuroprotective Effect of Fucoxanthin against Intracerebroventricular Streptozotocin (ICV-STZ) Induced Cognitive Impairment in Experimental Rats.

Authors:  Mahadev Dhami; Khadga Raj; Shamsher Singh
Journal:  Curr Alzheimer Res       Date:  2021       Impact factor: 3.498

6.  Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer's disease.

Authors:  Sónia C Correia; Renato X Santos; Maria S Santos; Gemma Casadesus; Joseph C Lamanna; George Perry; Mark A Smith; Paula I Moreira
Journal:  Curr Alzheimer Res       Date:  2013-05-01       Impact factor: 3.498

Review 7.  Molecular Basis of Familial and Sporadic Alzheimer's Disease.

Authors:  Jolanta Dorszewska; Michal Prendecki; Anna Oczkowska; Mateusz Dezor; Wojciech Kozubski
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

Review 8.  Transgenic mouse models of Alzheimer's disease.

Authors:  Gregory A Elder; Miguel A Gama Sosa; Rita De Gasperi
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb

Review 9.  Early-Onset Alzheimer's Disease: What Is Missing in Research?

Authors:  Temitope Ayodele; Ekaterina Rogaeva; Jiji T Kurup; Gary Beecham; Christiane Reitz
Journal:  Curr Neurol Neurosci Rep       Date:  2021-01-19       Impact factor: 5.081

Review 10.  The biological pathways of Alzheimer disease: a review.

Authors:  Marco Calabrò; Carmela Rinaldi; Giuseppe Santoro; Concetta Crisafulli
Journal:  AIMS Neurosci       Date:  2020-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.